Cardiol Therapeu Stock Price, News & Analysis

Cardiol Therapeutics (NASDAQ: CRDL) announced that full Phase II ARCHER trial data for CardiolRx will be presented on November 29, 2025 at the ESC Working Group on Myocardial & Pericardial Disease meeting in Trieste, Italy. Topline results reported improvements in extracellular volume and a significant reduction in left ventricular mass after twelve weeks of blinded therapy in acute myocarditis patients with preserved LV function.

The randomized, double-blind, placebo-controlled ARCHER trial enrolled 109 patients across the US, France, Brazil, and Israel. Cardiol will host a webcast and conference call on December 1, 2025 to discuss findings and next steps.

Cardiol Therapeutics (NASDAQ: CRDL) completed a private placement of 11.4 million units for US$11.4 million on October 21, 2025, funding operations into Q3 2027. Each unit = one common share plus one-half warrant; whole warrants exercise at US$1.35 for 24 months with an acceleration clause if VWAP > US$2.00 for five consecutive trading days. Proceeds fully fund the pivotal MAVERIC Phase III trial and advance CRD-38 through clinical development. New ARCHER trial data showing meaningful LV mass reduction will be presented at a November 2025 cardiology conference. Certain insiders participated under MI 61-101 exemptions.

Cardiol Therapeutics (NASDAQ: CRDL) completed a private placement for net proceeds of US$11 million (11 million Units at US$1.00), with US$10 million closed and US$1 million expected to close on Oct 20, 2025. Proceeds are anticipated to support operations into Q3 2027. Each Unit includes one common share and one-half warrant; whole warrants exercisable at US$1.35 for 24 months with an acceleration clause if shares exceed US$2.00 for five straight days.

The company says its pivotal MAVERIC Phase III program for CardiolRx is fully funded through a planned FDA NDA submission. New ARCHER trial data showed a significant reduction in LV mass, and next‑generation CRD‑38 is funded through clinical development with partnership discussions advancing.

Cardiol Therapeutics (NASDAQ: CRDL), a clinical-stage life sciences company developing treatments for heart disease, will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference. The event will take place in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT.

Investors can access the live webcast through the company's website, with a replay available for 90 days after the conference.

Cardiol Therapeutics (NASDAQ: CRDL) has announced topline results from its Phase II ARCHER trial evaluating CardiolRx™ in acute myocarditis. The trial demonstrated a notable improvement in left ventricular extracellular volume (p = 0.0538) compared to placebo after 12 weeks of treatment.

The study, which enrolled 109 patients across research centers in the US, France, Brazil, and Israel, showed improvements in multiple cardiac magnetic resonance imaging endpoints, including a significant reduction in left ventricular mass. CardiolRx™ maintained a favorable safety and tolerability profile, consistent with findings from the Phase II MAvERIC trial in recurrent pericarditis.

These results provide clinical proof of concept for CardiolRx™ and support advancing its development for cardiomyopathies, heart failure, and myocarditis. The findings will be submitted for presentation at an upcoming scientific meeting and publication.

Cardiol Therapeutics (NASDAQ: CRDL) has announced the database lock for its Phase II ARCHER trial investigating CardiolRx™ in acute myocarditis patients. The trial, which enrolled over 100 patients across research centers in the United States, France, Brazil, and Israel, is a multi-national, randomized, double-blind, placebo-controlled study.

The study's primary outcome measures evaluate cardiac magnetic resonance imaging parameters after 12 weeks of therapy, focusing on global longitudinal strain and extra-cellular volume. These parameters are crucial prognostic markers for myocarditis patients. Topline results are expected within two weeks of the database lock.

Notably, acute myocarditis currently has no FDA-approved drug therapies. The condition results in an average seven-day hospital stay with 4-6% in-hospital mortality risk, costing approximately $110,000 per stay in the United States.

Cardiol Therapeutics (NASDAQ: CRDL) held its Annual General Meeting of Shareholders on May 28, 2025, where shareholders approved all management resolutions. The company announced the election of eight directors, including new board member Dr. Timothy Garnett, former Chief Medical Officer at Eli Lilly. Dr. Garnett brings over 30 years of pharmaceutical industry experience and will help guide the company's strategic priorities.

The company is currently advancing two key clinical trials: the Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and the Phase II ARCHER trial of CardiolRx™ in acute myocarditis, with the latter preparing for database lock and top-line results reporting. Michael Willner, who served as a Board member since September 2021, will continue in an advisory capacity.

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL), a clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart disease treatment, has announced its virtual Annual General Meeting of Shareholders (AGM). The meeting will be held on May 28, 2025, at 4:30 p.m. EDT via live audio webcast at web.lumiagm.com/226536161. Shareholders can find detailed information about participation and voting procedures on the company's website at cardiolrx.com/investors/events-presentations/.

Cardiol Therapeutics has nominated Dr. Timothy Garnett to its Board of Directors, bringing over 30 years of pharmaceutical industry expertise. Dr. Garnett, the former Chief Medical Officer of Eli Lilly (2008-2021), will stand for election at the Company's 2025 Annual General Meeting on May 28.

During his tenure at Eli Lilly, Dr. Garnett led successful therapeutic developments in:

• Women's health
• Endocrinology
• Neuroscience

The nomination coincides with Cardiol's milestone of initiating patient enrollment in their pivotal Phase III MAVERIC trial. Dr. Garnett currently serves as Chair of Ophirex, Director of MapLight Therapeutics, and holds advisory roles at Cambridge Innovation Capital and Recode Health Ventures. His expertise in clinical development and regulatory approval processes aligns with Cardiol's mission to develop anti-inflammatory and anti-fibrotic therapies for heart disease treatment.